Italia markets closed
FTSE MIB
33.154,05 -32,84 (-0,10%) Dow Jones
39.118,86 -45,20 (-0,12%) Nasdaq
17.732,60 -126,08 (-0,71%) Nikkei 225
39.583,08 +241,54 (+0,61%) Petrolio
81,46 -0,28 (-0,34%) Bitcoin EUR
56.574,72 -733,79 (-1,28%)
NBIX Nov 2024 185.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 09:30AM EDT
| Chiusura precedente | 2,1000 |
| Aperto | 2,1000 |
| Denaro | 0,0000 |
| Domanda | 0,0000 |
| Prezzo d'esercizio | 185,00 |
| Scadenza | 2024-11-15 |
| Min-Max giorno | 2,1000 - 2,1000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 22 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.